Association between plasma glycocalyx component levels and poor prognosis in severe influenza type A (H1N1)

Xiao Huang1,4, Feng Lu1,4, Huanhuan Tian1,4, Haoran Hu3, Fangyu Ning1, Quanmei Shang1, Dong Hao2, Weiwei Zhu2, Guiqing Kong1, Xiaohong Ma2, Jiali Feng3, Tao Wang1 & Xiaozhi Wang1

Influenza A virus infection causes a series of diseases, but the factors associated with disease severity are not fully understood. Disruption of the endothelial glycocalyx contributes to acute lung injury in sepsis, but has not been well studied in H1N1 influenza. We aim to determine whether the plasma glycocalyx components levels are predictive of disease severity in H1N1 influenza. This prospective observational study included 53 patients with influenza A (H1N1) during the influenza season, and 30 healthy controls in our hospital. Patients were grouped by severity and survival. We collected clinical data and blood samples at admission. Inflammatory factors (tumor necrosis factor-α, interleukin-6, interleukin-10) and endothelial glycocalyx components (syndecan-1, hyaluronan, heparan sulfate) were measured. The plasma levels of syndecan-1, hyaluronan, and heparan sulfate were significantly higher in patients with severe influenza A (H1N1) than in mild cases. Syndecan-1 and hyaluronan were positively correlated with disease severity, which was indicated by the APACHE II and SOFA scores and lactate levels, and negatively correlated with albumin levels. At a cutoff point ≥ 173.9 ng/mL, syndecan-1 had a 81.3% sensitivity and 70.3% specificity for predicting of 28-day mortality. Kaplan–Meier analysis demonstrated a strong association between syndecan-1 levels and 28-day mortality (log-rank 11.04, P = 0.001). Elevated plasma levels of syndecan-1 has a potential role in systemic organ dysfunction and may be indicative of disease severity in patients with influenza A (H1N1).

Influenza is a viral disease, caused by infection with influenza A (or B) virus. Clinical symptoms range from mild to severe (including acute respiratory distress syndrome (ARDS))1,2. According to World Health Organization reports (http://www.who.int/mediacentre/factsheets/fs211/en/), influenza causes global annual infection rates of 5%–10% in adults, 3–5 million cases of severe illness, and between 290,000 and 650,000 deaths annually worldwide. Neuraminidase inhibitors (NAIs) are approved for both influenza A and B virus infections; early antiviral therapy with NAIs can improve the outcome of influenza A2; however, a small number of patients experience a rapid progression to primary viral pneumonia or secondary bacterial infections, resulting in a significant number of deaths despite the use of antivirals3. Therefore, improving antivirals alone may not be sufficient to minimize morbidity and mortality, and the pathogenesis of influenza A needs to be further explored.

Severe influenza virus infections cause a dysregulated inflammatory response, leading to the release of pro-inflammatory cytokines in the lungs and blood, a condition often referred to as a "cytokine storm"4. Inflammatory cytokines can lead to diffuse alveolar damage, and interstitial and airspace inflammation, which adversely affect outcomes in patients with severe influenza5,6. An abnormal immune response to influenza A can lead to endothelial damage, alteration of microvascular permeability, tissue edema, deregulation of coagulation, and even shock7,8.

Influenza A can directly and indirectly cause lung endothelial cell activation and injury, inducing microvascular leakage9. The surface of the vascular endothelium is coated with a "thick" glycocalyx, a dynamic and complex
biochemical structure consisting of core proteins (syndecans and glypicans) and glycosaminoglycan chains (heparan sulfate [HS], hyaluronic [HA] etc.), which play a key role in limiting vascular permeability and regulating platelet and leukocyte adhesion. Syndecan-1 (SDC-1) belongs to the family of syndecans, and is involved in leukocyte recruitment, the chemokine gradient, and extracellular matrix remodeling during inflammatory diseases; it also plays a pivotal role in glycoscalyx integrity and function. Glycoscalyx dysfunction and component shedding have been described in many clinical pathophysiologic processes, including sepsis, ARDS, and coronavirus disease 2019 (COVID-19). Furthermore, elevated plasma SDC-1 and HA levels are associated with cumulative fluid volumes, degree of organ failure, and increased mortality in patients with sepsis. Lipopolysaccharide-induced shedding of HS in the pulmonary endothelial glycoscalyx uncovers endothelial cell surface molecules, thereby accelerating neutrophil adhesion and alveolar exudation. Benatti et al. reported that a higher level of HA and SDC-1 in flu syndromes with the ARDS group is observed compared to those without ARDS. These findings suggest that endothelial glycoscalyx shedding occurs during the virus-induced ARDS installation. Thus, the role of endothelial glycoscalyx injury and activation in the pathogenesis of ARDS caused by sepsis and flu is known, but the role of the endothelial glycoscalyx in influenza 

A (H1N1) severity has not been elucidated. However, the effect of the components of the glycoscalyx on the prediction disease severity of influenza A (H1N1) needs to be further investigated.

We further hypothesized that the degree of endothelial glycoscalyx degradation is associated with severity and mortality in patients with influenza A(H1N1). In this study, we aimed to determine whether the plasma levels of glycoscalyx components are indicative of influenza A (H1N1) severity.

Materials and methods

Study design and patient recruitment. This prospective observational study included patients admitted to the Department of Pulmonary and Critical Care Medicine (72 beds) and intensive care unit (48 beds) of Binzhou Medical University Hospital (Binzhou, Shandong, China) during a period of the influenza season from November 2017 to March 2018 and from November 2018 to March 2019. The inclusion criteria were the age of ≥ 18 years, and should be an influenza-positive PCR test from an airway specimen. Viral specimens were collected from November 2017 to March 2018 and from November 2018 to March 2019. The inclusion criteria were of Binzhou Medical University Hospital (Binzhou, Shandong, China) during a period of the influenza season.

Caregivers and healthy controls before enrollment.

A protocol was approved by the Ethics Committee of the Binzhou Medical University Hospital, and was registered in the Clinical Trials Register (ChiCTR200004921). Informed consent was obtained from patients (or their caregivers) and healthy controls before enrollment.

Data and blood sample collection. Demographic characteristics, including sex, age, comorbidity, and symptoms at onset of illness, were recorded on admission. The Sequential Organ Failure Assessment (SOFA) score, and the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score were calculated to assess illness severity. Clinical outcomes were assessed according to the 28-day mortality rate.

On the first medical diagnosis, a venous blood sample was collected in a K2 EDTA tube. Venous blood samples were collected from the patients and centrifuged at 4000×g for 10 min, and plasma was collected and stored at –80 °C until analysis. The lactate level, blood routine index, hepatic and renal function, and coagulation/fibrinolysis markers were analyzed in a standardized laboratory. Plasma levels of tumor necrosis factor-α (TNF-α) (Besançon cedex, France, 950.090.096, Diaclone), interleukin-6 (IL-6) (Besançon cedex, France, 950.090.096, Diaclone), interleukin-10 (IL-10) (Besançon cedex, France, 950.060.096, Diaclone), SDC-1 (Besançon cedex, France, 950.640.096, Diaclone), HA (Minneapolis, USA, DHYAL0, R&D Systems), and HS (San Diego, USA, 950.030.096, Diaclone) and IL-10 (Besançon cedex, France, 950.060.096, Diaclone), SDC-1 (Besançon cedex, France, 950.640.096, Diaclone), HA (Minneapolis, USA, DHYAL0, R&D Systems), and HS (San Diego, USA, MBS285287, MyBioSource) were measured using an enzyme-linked immunosorbent assay kit according to the manufacturer’s instructions.

Statistical analysis. All categorical variables are expressed as numbers and percentages. Between-group comparisons of frequencies were analyzed using the chi-square test. Summary statistics for normally distributed continuous variables are presented as mean ± standard deviation, and non–normally distributed continuous variables are presented as median and interquartile range. Differences between groups were tested for significance using either the non–parametric Mann–Whitney U test or an unpaired Student’s t-test for two groups and the Kruskal–Wallis analysis of variance for multiple groups. Correlations were analyzed by the Spearman rank correlation test. The efficacy of each parameter in predicting the diagnostic power of each marker is expressed as the area under curve (AUC) using the receiver operating characteristic (ROC) analysis. Kaplan–Meier analysis was performed to compare the outcome of groups according to the SDC-1 cut–off. Survival curves were compared using a log–rank test. For all tests, a P-value of less than 0.05 was considered statistically significant. Statistical analyses were conducted using IBM SPSS 25.0.

Results

Patient characteristics. We initially screened 59 hospitalized patients with a high suspicion of influenza A infection (Fig. 1). We excluded one patient with avian influenza H7N9, and five patients with influenza B antigen (+). Thus, we enrolled 53 patients with a positive PCR test for influenza A (H1N1) and 30 healthy controls. The 30 healthy controls comprised 15 men and 15 women with a median age of 59 years. The 53 patients with influenza A (H1N1) comprised 20 men (37.73%) and 33 women (62.26%) with a median age of 57 years.

Using
the program for diagnosis and treatment of influenza A (H1N1), H1N1-infected patients were divided into two different groups based on clinical severity: the mild group (n = 15) and the severe group (n = 38). The patient characteristics are presented in Table 1.

The most common clinical features at illness onset included a fever of > 38°C (n = 35, 66.04%), cough (n = 42, 79.25%), sputum production (n = 33, 62.26%), oppression, (n = 22, 41.51%) and chilly (n = 14, 26.41%). Less common symptoms were myalgia, chest pain, pharyngalgia, anorexia, etc. The most common comorbidities were hypertension (n = 15, 28.30%), cardiovascular disease (n = 6, 11.32%), and diabetes (n = 8, 15.09%); however, 9 patients presented without comorbidity. Two patients in the mild group presented with asthma; this comorbidity was not present among patients in the severe group. The P/F ratio tended to be lower in the severe group than in the mild group. Invasive mechanical ventilation was required in > 50% of the patients in the severe group. There was no statistically significant difference in the number of patients taking steroid treatment between the two groups. The length of hospital stay was significantly longer in the severe group than in the mild group. All participants were followed-up for 28 days, at which point there were 37 survivors and 16 non-survivors.

Laboratory records and inflammation markers. The median white blood count in both the mild and severe groups were within the normal range; however, the count was significantly higher in the severe group; 50% of the patients in the severe group had white blood cell counts of > 10^9/L. The lymphocyte count and percentage were significantly lower in the severe group than in the mild group. The alanine aminotransferase (ALT) levels were higher than 35 U/L in 17 patients in the severe group and four in the mild group. The aspartate aminotransferase (AST) levels were higher than 40 U/L in 24 patients in the severe group and one in the mild group. Concurrently, the proportion of patients with increased AST was significantly higher in the severe group than in the mild group (24/38 [63.16%] vs. 1/15 [6.67%], P < 0.001). The lactate dehydrogenase and procalcitonin levels were significantly higher in the severe group than in the mild group. However, the albumin level was significantly lower in the severe group than in the mild group. The severe group also exhibited marked increases in TNF-α, IL-6, and IL-10 levels relative to the mild group. The laboratory findings and inflammation markers of patients with influenza A (H1N1) are presented in Table 2.

Glycocalyx component levels and biomarker accuracy. The plasma levels of SDC-1 (257.9 [142.1–658.8] vs. 58.6 [49.4–75.9] ng/ml), HA (334.4 [159.3–413.9] vs. 156.6 [116.1–230.5] ng/ml), and HS (305.1
Table 1. Characteristics and symptoms of patients infected with Influenza A (H1N1). Data are expressed as median (inter-quartile range), mean ± SD, or number (%). Abbreviations: APACHE, Acute Physiology, Age, Chronic Health Evaluation; SOFA, Sequential organ failure assessment; P/F, PaO2/FiO2. a, vs. Mild group, χ² tests; b, vs. Mild group, Mann–Whitney U test. Kruskal–Wallis test was used between the age of control, mild and severe groups; χ² test was used between the male to female ratio of control, mild and severe groups. –, This data were not collected initially.

| Characteristics                                      | Control subjects (N=30) | Total Influenza A (H1N1) (N=53) | Mild Influenza A (H1N1) (N=15) | Severe Influenza A (H1N1) (N=38) | P Value |
|------------------------------------------------------|-------------------------|---------------------------------|-------------------------------|---------------------------------|---------|
| Age, years (Median, P25-P75)                         | 59 (53–63)              | 57 (47, 69)                     | 56 (47, 76)                   | 59 (44, 69)                     | 0.96    |
| Sex (Male/Female)                                    | 15/15                   | 20/33                           | 7/8                           | 13/25                           | 0.393   |
| Smoker (n, %)                                        | 8, 26.67%               | 20, 37.73%                      | 10, 66.67%                    | 10, 26.32%*                    | 0.006   |
| Lactate (mmol/L)                                     | -                       | 1.5 (1.0, 2.7)                  | 1.1 (0.9, 1.5)                | 2.1 (0.9, 3.1)*                | 0.012   |
| ≥ 2 (n, %)                                           | 21, 39.62%              | 1, 6.67%                        | 20, 52.63%*                   | 20, 52.63%*                    | 0.002   |
| APACHE II score                                      | -                       | 11 (8, 15)                      | 8 (5, 9)                      | 14 (10,18)*                    | <0.001  |
| SOFA score                                           | -                       | 5 (2, 7)                        | 2 (1, 2)                      | 6 (4, 8)*                      | <0.001  |
| Comorbidity (n, %)                                   | -                       |                                 |                               |                                 |         |
| Hypertension                                         | 15, 28.30%              | 2, 13.33%                       | 13, 34.21%                    | 0.129                           |
| Cardiovascular disease                               | 6, 11.32%               | 2, 13.33%                       | 4, 10.53%                     | 0.771                           |
| Diabetes                                             | 8, 15.09%               | 1, 6.67%                        | 7, 18.42%                     | 0.282                           |
| Cerebrovascular disease                              | 3, 5.66%                | 1, 6.67%                        | 2, 5.26%                      | 0.842                           |
| Chronic obstructive disease                          | 3, 5.66%                | 1, 6.67%                        | 1, 2.63%                      | 0.487                           |
| Asthma                                               | 2, 3.77%                | 2, 13.33%                       | 0, 0*                         | 0.022                           |
| Chronic hepatitis                                    | 2, 3.77%                | 0, 0                            | 2, 5.26%                      | 0.365                           |
| Malignancy                                           | 3, 5.66%                | 2, 13.33%                       | 1, 2.63%                      | 0.144                           |
| Without                                              | 9, 16.98%               | 1, 6.67%                        | 8, 21.05%                     | 0.209                           |
| Symptoms at onset of illness                         | -                       |                                 |                               |                                 |         |
| Highest temperature, °C                              | 38.5 (38.0, 39.1)       | 38.6 (37.9, 39.1)               | 38.5 (38.0, 39.1)             | 0.993                           |
| <37.3 (n, %)                                         | 5, 9.43%                | 2, 13.33%                       | 3, 7.89%                      | 0.542                           |
| 37.3–38 (n, %)                                       | 13, 24.53%              | 3, 20.00%                       | 10, 26.31%                    | 0.630                           |
| 38.1–39 (n, %)                                       | 19, 35.85%              | 6, 40.00%                       | 13, 34.21%                    | 0.692                           |
| >39 (n, %)                                           | 16, 30.19%              | 4, 26.67%                       | 12, 31.58%                    | 0.726                           |
| Cough (n, %)                                         | 42, 79.25%              | 11, 73.33%                      | 31, 81.58%                    | 0.505                           |
| Sputum production (n, %)                             | 33, 62.26%              | 9, 60.00%                       | 24, 41.38%                    | 0.831                           |
| Oppression (n, %)                                    | 22, 41.51%              | 9, 60.00%                       | 13, 34.21%                    | 0.086                           |
| Chilly (n, %)                                        | 14, 26.41%              | 4, 26.67%                       | 10, 26.32%                    | 0.979                           |
| Fatigue (n, %)                                       | 8, 15.09%               | 2, 13.33%                       | 6, 11.32%                     | 0.822                           |
| Myalgia (n, %)                                       | 5, 9.43%                | 2, 13.33%                       | 3, 5.17%                      | 0.542                           |
| Headache (n, %)                                      | 3, 5.66%                | 2, 13.33%                       | 1, 2.63%                      | 0.129                           |
| Chest pain (n, %)                                    | 4, 7.55%                | 3, 20.00%                       | 1, 2.63%*                     | 0.031                           |
| Pharyngalgia (n, %)                                  | 3, 6.66%                | 1, 6.67%                        | 2, 3.45%                      | 0.842                           |
| Anorexia (n, %)                                      | 5, 9.43%                | 0, 0                            | 5, 8.62%                      | 0.134                           |
| Vomiting (n, %)                                      | 1, 1.88%                | 0, 0                            | 1, 1.72%                      | 0.526                           |
| Dizziness (n, %)                                     | 3, 5.66%                | 1, 6.67%                        | 2, 3.45%                      | 0.842                           |
| P/F ratio                                            | 223 (112, 311)          | 328 (297, 366)                  | 164 (76, 205)*                | <0.001                          |
| During hospitalization stay Ventilatory support (n, %)|                       |                                 |                               |                                 |         |
| Nasal catheters for oxygen                           | 10, 66.67%              | 2, 5.26%                        | 6, 15.79%                     | 0.993                           |
| Non invasive ventilation                             | 0, 0                    | 6, 11.32%                       | 8, 21.05%                     | 0.822                           |
| High flow nasal cannula                              | 0, 0                    | 22, 57.89%                      | 14, 36.84%                    | 0.831                           |
| Invasive mechanical ventilation                      | 0, 0                    | 14, 36.84%                      | 14, 36.84%                    | 0.831                           |
| Steroid treatment                                    | 20, 37.74%              | 6, 40.00%                       | 14, 36.84%                    | 0.831                           |
| Hospital length of stay, days                        | 11 (6, 18)              | 8 (6, 14)                       | 14 (9, 21)*                   | 0.044                           |
| ICU length of stay, days                             | -                       | 9 (4, 13)                       | 16, 42.11%                    | 0.044                           |
| 28-day mortality, (n, %)                             | 16, 30.19%              | 9 (4, 13)                       | 16, 42.11%                    | 0.044                           |
[193.9–516.9] vs. 228.8 [198.9–312.4] ng/ml) were significantly higher in the severe group than in the mild group (Fig. 2). We conducted a ROC analysis to determine the utility of glycocalyx components as markers of severe disease. The diagnostic accuracy for the identification of patients progressing to severe influenza A (H1N1) was highest for SDC-1, with an AUC of 0.942 (95% CI: 0.881–1.000; \( P < 0.001 \); Fig. 2d). At a cutoff point of > 81.0 ng/mL, SDC-1 had a sensitivity of 92.1% and specificity of 86.7% for diagnosing severe influenza A (H1N1).

**SDC-1 levels and disease severity.** To identify the clinical relevance of endothelial glycocalyx components, we analyzed the correlation between the following variables: SDC-1, HA, and HS levels; SOFA score; APACHE II score; and various biochemical parameters including lactate, albumin, inflammatory markers (TNF-α, IL-6, and IL-10), and global hemostatic markers (platelet count and D-dimer).

Spearman’s correlation analysis showed that the SDC-1 and HA levels were significantly correlated with the APACHE II (\( r = 0.526, P < 0.001 \); \( r = 0.439, P = 0.001 \)) and SOFA scores (\( r = 0.515, P < 0.001 \); \( r = 0.409, P = 0.002 \)) (Table 3, Supplementary Fig. 1). High lactate level is traditionally considered as a marker of tissue hypoxia, and can be considered as a warning signal for organ dysfunction19. Among the glycocalyx components, lactate levels were significantly positively correlated with SDC-1 (\( r = 0.392, P = 0.004 \)) and HA (\( r = 0.372, P = 0.006 \)) (Table 3, Supplementary Fig. 1). SDC-1 and HA were negatively correlated with the platelet count and positively correlated with the D-dimer concentration.

Table 2. Laboratory records and inflammation markers of patients infected with Influenza A (H1N1) on admission. Data are expressed as median (inter-quartile range), mean ± SD, or number (%). Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; LDH, Lactate dehydrogenase; CK, Creatine kinase; PCT, Procalcitonin; TNF, tumor necrosis factor; IL-6, interleukin-6; IL-10, interleukin-10. \( a \), vs. Mild group, \( \chi^2 \) tests; \( b \), vs. Mild group, Mann–Whitney U test; \( c \), unpaired Student t test. \( d \), vs. Control group, Kruskal–Wallis test. –, This data were not collected initially.
(Table 3, Supplementary Fig. 3). We also observed that SDC-1 and HA were positively correlated with IL-6 and IL-10 levels (Table 3, Supplementary Fig. 4).

**Predictors of 28-day mortality.** All study participants were followed-up for 28 days and divided into the survivor and non-survivor groups (Table 4). The APACHE II and SOFA scores and lactate, D-dimer, IL-6,
IL-10, SDC-1, and HA levels were significantly higher in non-survivors than in survivors. The albumin level and lymphocyte percentage were significantly lower in non-survivors than in survivors. We constructed ROC curves to determine the sensitivity and specificity of the APACHE II and SOFA scores, laboratory records, inflammation markers, and endothelial glycocalyx markers, in order to predict 28-day mortality (Fig. 3). The AUC for the SDC-1 was 0.855 (95% CI 0.75–0.96), which was higher than that for other indicators. At a cutoff point of ≥ 173.9 ng/ml, SDC-1 provided a specificity of 81.3% and a sensitivity of 70.3% for predicting 28-day mortality. Kaplan–Meier survival analyses are shown in Fig. 4. Patients with plasma SDC-1 ≥ 173.9 ng/ml had a significantly higher 28-day mortality estimate than patients with plasma SDC-1 < 173.9 ng/ml (P = 0.001).

Table 4. The APACHE II and SOFA scores, laboratory records, inflammation markers, and endothelial glycocalyx markers in the survivors and non-survivors (28-day death) on the admission. Data are expressed as median (inter-quartile range), mean ± SD, or number (%). Abbreviations: APACHE, Acute Physiology, Age, Chronic Health Evaluation; SOFA, Sequential organ failure assessment; TNF, tumor necrosis factor; IL-6, interleukin-6; IL-10, interleukin-10; SDC-1, syndecan-1; HS, heparan sulfate; HA, hyaluronan. b, vs. Mild group, Mann–Whitney U test; c, unpaired Student t test.

| Characteristics                  | Survivor (N = 37) | Non-survivor (N = 16) | P Value |
|----------------------------------|------------------|-----------------------|---------|
| APACHE II score                  | 9 (7, 13)        | 15 (14, 18)b          | < 0.001 |
| SOFA score                       | 3 (2, 6)         | 7 (5, 9)b             | 0.001   |
| Lactate                          | 1.2 (0.9, 1.6)   | 2.2 (1.5, 3.5)b       | 0.001   |
| Lymphocyte count, × 109/L        | 0.9 (0.5, 1.4)   | 0.6 (0.3, 0.9)b       | 0.048   |
| Lymphocyte percentage            | 11.5 (7.1, 18.6) | 5.4 (4.2, 7.8)b       | 0.002   |
| Platelet                         | 210.5 (144.0, 272.0) | 136.5 (85.5, 230.0)b | 0.075   |
| D-dimer (μg/mL)                  | 1.52 (0.49, 3.72) | 6.26 (2.27, 22.1)b    | 0.012   |
| Albumin, g/L                     | 32.2 ± 6.6       | 27.2 ± 4.2c           | 0.007   |
| Inflammation markers             |                  |                       |         |
| TNF-α (pg/ml)                    | 11.6 (8.4, 21.6) | 14.1 (10.0, 35.7)°   | 0.322   |
| IL-6 (pg/ml)                     | 15.4 (4.5, 96.7) | 82.5 (15.8, 376.1)b  | 0.046   |
| IL-10 (pg/ml)                    | 11.27 (7.0, 23.1) | 30.1 (14.1, 57.6)b  | 0.036   |
| Endothelial glycocalyx markers   |                  |                       |         |
| SDC-1 (ng/ml)                    | 117.7 (65.3, 258.5) | 576.3 (204.7, 755.3)b | 0.003   |
| HA (ng/ml)                       | 190.4 (108.4, 348.2) | 400.5 (213.1, 431.3)b | 0.02    |
| HS (ng/ml)                       | 233.8 (178.8, 331.7) | 419.7 (201.4, 1446.6)b | 0.034   |

Figure 3. ROC curves for the prediction of 28-day mortality in patients with influenza A (H1N1).
In this study, we aimed to determine whether the plasma levels of glycocalyx components are indicative of influenza A (H1N1) severity. We found that SDC-1, HS, and HA levels were significantly higher in patients with severe influenza A (H1N1) than in patients with mild disease. In addition, the severity of endothelial glycocalyx shedding was closely associated with disease severity, and facilitated the identification of patients with severe influenza A (H1N1). Furthermore, we found that the level of SDC-1 was a good predictor for 28-day mortality among patients with influenza A (H1N1). To our knowledge, this study is the first to compare plasma glycocalyx components in patients with mild and severe influenza A (H1N1).

Pandemic 2009 influenza A (H1N1) viral infections continue to be a public health threat. Influenza A (H1N1)-infected patients most often have a mild clinical course; but the mortality rate is higher in severe cases. Naudion et al. reported that nineteen patients (9.1%) died in the hospital during the study period. Lobo et al. reported that the mortality rate for patients with severe acute respiratory infection in the influenza A (H1N1) positive was 29.5%. In our study, the 28-day mortality rate of severe H1N1 patients was 42.1%. Furthermore, we found that approximately 21% of patients with severe H1N1 had no underlying disease. Several studies have found that both young subjects and adults may develop a severe clinical course of H1N1 infection without having any known risk factors. The underlying pathogenic mechanisms have not been fully elucidated. In the ICU, patients with influenza A (H1N1) often present with viral pneumonia, severe hypoxemic respiratory failure, and ARDS. Currently, treatment for patients with severe influenza A (H1N1) is limited to antiviral drugs and symptomatic treatment, and which mainly consists of the optimization of oxygen supply and transfer through ventilation.

The severity of influenza A has been attributed to a systemic and inflammatory process that damages not only the lungs, but also multiple organs, including the central nervous system and cardiovascular system. In our study, we found that patients with severe influenza A (H1N1) had increased levels of D-dimer, indicating coagulation disorders. The multiple organ damage caused by influenza may be due to inflammation and vascular endothelial cell injury. The cytokines storms caused by influenza have been associated with pro-inflammatory response disorder, which may lead to significant pathological consequences and poor prognosis. The levels of pro-inflammatory cytokines are closely related to outcomes in patients with severe influenza. This is consistent with our observation of significantly higher levels of inflammatory cytokines (IL-6 and IL-10) in non-survivors compared to survivors.

The levels of endothelial glycocalyx components, including SDC-1, HS, and HA, are useful biomarkers for sepsis, ARDS, and COVID-19. Further, the APACHE II and SOFA scores may be used to assess the risk of death in critically ill patients, regardless of the primary disease. We found that plasma levels of SDC-1 and HA were significantly higher in patients with severe H1N1 than in patients with mild H1N1, and were positively correlated with the APACHE II and SOFA scores. Furthermore, at a cutoff point of ≥ 173.9 ng/ml, SDC-1 showed a specificity of 81.3% and sensitivity of 70.3% for predicting 28-day mortality. The plasma SDC-1 levels ≥ 173.9 ng/ml were associated with mortality in hospitalized patients with influenza A (H1N1) virus infection.
A few of the pathophysiological features of severe influenza pneumonia include small vessel thrombosis, hemorrhage, and diffuse alveolar damage. The surface of vascular endothelium is coated with glycocalyx, which is extremely important for the maintenance of antithrombogenicity in the vascular lumen. Disturbance of the glycocalyx is often due to the increased expression and release of proteases (matrix metalloproteinases) and glycosidases (e.g., hyaluronidases and heparinase). Aggregation of activated platelets within the pulmonary microvasculature promotes lung inflammation and injury; shedding of the glycocalyx results in promoted platelet aggregation and adhesion to the endothelium and subsequent thrombi formation. We previously found that an increasing level of SDC-1 can be used as a biomarker for predicting diffuse intravascular coagulation (DIC) development with sepsis and that non-anticoagulant heparin can improve coagulation by inhibiting the activity of heparinase and reducing the shedding of glycocalyx in sepsis. It is well known that a sharp increase in D-dimer, a secondary fibrinolytic specific molecular marker, typically indicates the existence of a thrombus. We observed a significant negative correlation between plasma albumin levels and the shedding of glycocalyx. Albumin has multiple biological activities, including antioxidant effects, and maintains vessel wall integrity. Although albumin has a net negative charge, its amphoteric nature promotes tight binding to the glycocalyx, with the net effects of reducing hydraulic conductivity across the vascular barrier, resisting glycocalyx degradation (i.e., protecting against shedding), and contributing to the maintenance of vascular integrity and normal capillary permeability. We showed that 5% albumin prevented glycocalyx degradation more effectively than did HES (6% hydroxyethyl starch 130/0.4) and 0.9% normal saline in their animal heart model. We believe that the effectiveness of albumin administration in preventing glycocalyx degradation in severe influenza or ARDS needs to be further explored.

Our study has several limitations. First, this study was conducted at a single center and involved a relatively small number of patients with influenza A (H1N1); our findings require large-scale clinical validation in order to be generalized. Therefore, our data should be interpreted with caution. Second, the data presented here were based on single time-point measurements and were not consecutive, the dynamic change was unknown, and the predictive value needs further evaluation. Despite the above limitations, we believe that our study has yielded important and novel findings regarding the prediction of mortality in hospitalized patients with influenza A (H1N1).

Conclusions

Plasma glycocalyx component levels are significantly higher in patients with severe influenza A (H1N1) than in mild cases. Specifically, SDC-1 and HA are closely correlated with APACHE II and SOFA scores, albumin, platelets, and D-dimer. Plasma SDC-1 levels of ≥ 173.9 ng/ml were associated with 28-day mortality in patients with influenza A (H1N1). Thus, increased plasma SDC-1 may be a biomarker of disease severity and could be useful for predicting 28-day mortality in patients with influenza A (H1N1).

Ethics approval statement

This study was performed in accordance with the Declaration of Helsinki and approved by research ethics board of Binzhou Medical University Hospital. The study was registered in the Clinical Trials Register (ChiCTR2000040921).

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Received: 8 May 2021; Accepted: 29 November 2021
Published online: 07 January 2022

References

1. Fauci, A. S. Seasonal and pandemic influenza preparedness: science and countermeasures. J. Infect Dis. 194, S73–S76 (2006).
2. Reed, C. et al. Complications among adults hospitalized with influenza: a comparison of seasonal influenza and the 2009 H1N1 pandemic. Clin. Infect. Dis. 59, 166–174 (2014).
3. Louie, J. K. et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin. Infect. Dis. 55, 1198–1204 (2012).
4. Tavares, L. P., Teixeira, M. M. & Garcia, C. C. The inflammatory response triggered by Influenza virus: a two edged sword. Inflammm. Res. 66(4), 283–302 (2017).
5. Short, K. R., Kedzierska, K. & van de Sandt, C. E. Back to the future: lessons learned from the 1918 influenza Pandemic. Front. Cell Infect Microbiol. 8, 343 (2018).
This study was supported by National Natural Science Foundation of China (Grant No. 81670078), Natural Science Foundation of Shandong Province (Grant No. ZR2019PH049), and the Medicine and Health Science Technology Development Plan of Shandong Province (Grant No. 2018WS0049), Taishan Scholar Project of Shandong Province, Key Clinical Specialty Project of Shandong Province.

Acknowledgements

This study was supported by National Natural Science Foundation of China (Grant No. 81670078), Natural Science Foundation of Shandong Province (Grant No. ZR2019PH049), and the Medicine and Health Science Technology Development Plan of Shandong Province (Grant No. 2018WS0049), Taishan Scholar Project of Shandong Province, Key Clinical Specialty Project of Shandong Province.
Author contributions
X. H., F. L. and H.H. T. drafted the study and wrote the manuscript. H.R. H., Q.M. S., D. H. and W.W. Z. performed the statistical analyses and interpreted the data. G.Q. K., F.Y. N., X.H. M. and J.L. F. contributed biomarker measurements and analyses. T. W. and X.Z. W. supervised the study design, data interpretation, and manuscript preparation. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-04146-2.

Correspondence and requests for materials should be addressed to T.W. or X.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022